Navigation Links
Medical Device Industry Executive Joins OrthoAccel Technologies, Inc. Board of Directors
Date:10/14/2010

HOUSTON, Oct. 14 /PRNewswire/ -- OrthoAccel Technologies, Inc., developers of the AcceleDent System, an acceleration device to enhance orthodontics, announced this week that it has engaged Todd Cooper as a Director on its Corporate Board.  Mr. Cooper's directorship will involve oversight and corporate governance of the Company's business strategy, with a focus on market growth.

(Logo:  http://photos.prnewswire.com/prnh/20091029/DA01250LOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20091029/DA01250LOGO)

AcceleDent is a simple, removable dental device that an orthodontic patient wears in the mouth for 20 minutes daily to accelerate orthodontic tooth movement.  A Phase I clinical trial in 2008 in Houston, Texas demonstrated the safety of the device.  The first completed AcceleDent case in private practice was documented earlier this month in the United Kingdom.

Mr. Cooper's background is particularly relevant to OrthoAccel's development of the AcceleDent brand.  His extensive experience includes general management, sale, marketing and product development on a global basis.  While at Discus, a market leader across numerous dental aesthetic  product categories, his leadership resulted in aggressive revenue growth and increasing profitability.  Most recently, Mr. Cooper managed the $400 million medical surgical business at Henry Schein, a $6.5 billion life sciences company.

Michael Lowe, CEO of OrthoAccel, commented, "We knew immediately that Todd's insight could help us shape our strategic direction.  There are many important parallels between OrthoAccel and the businesses that he has successfully managed in the past."  Mr. Cooper remarked, "AcceleDent can revolutionize the orthodontic market space and has huge market potential globally, much like Discus' whitening products did in the aesthetic space. AcceleDent addresses the fundamental desire by patients to shorten the time they need to use orthodontic appliances. I look forward to actively working with the Board and Management Team to build a strong global business."

Last month, OrthoAccel attended the British Orthodontic Conference, where it hosted a reception to feature the learnings from a select group of orthodontic specialist doctors who had been using the product for about a year.  Later this month, a lecture series will be held in Australia, where the device is also available, to further generate awareness around the AcceleDent science and favorable clinical outcomes.  This event is being coordinated in conjunction with AB Orthodontics, the exclusive distributor of AcceleDent in Australia.

OrthoAccel is nearing conclusion of another US clinical trial at the UT Health Science Center in San Antonio with an anticipated completion date in 2010.

About OrthoAccel Technologies, Inc.

Based in Houston, Texas, OrthoAccel Technologies, Inc. is a privately owned medical device company currently engaged in the development, manufacturing, and marketing of products to enhance dental care and orthodontic treatment.

About the AcceleDent System

AcceleDent represents the first clinical approach to safely accelerate orthodontic tooth movement via modulating biology.  The device has been studied clinically and applies gentle pulsing forces in combination with standard orthodontics to move teeth faster through accelerated bone remodeling.  Importantly, the device works complementary with all existing orthodontic technologies.  AcceleDent is neither FDA cleared nor FDA approved; it is currently investigational only in the United States.  More information can be found at www.acceledent.com or requested via info@orthoaccel.com


'/>"/>
SOURCE OrthoAccel Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. Globus Medical Raises $110 Million in Series E Financing Round
5. Quark Pharmaceuticals Appoints New Chief Medical Officer
6. Boston University Biomedical Engineers Find Chink in Bacterias Armor
7. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
8. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
9. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
10. Cleveland Clinic Summits to Focus on Cardiovascular Medical Innovation
11. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... MedDay, a biotechnology company focused on the treatment ... "High doses of biotin in progressive multiple sclerosis: extension phase ... Ayman Tourbah , Principal Investigator of the Phase 3 ... Neurology (EAN) in Copenhagen, Denmark . The ... on Sunday, 29 May 2016 from 14:45 to 16:15 CEST ...
(Date:5/24/2016)... --   , ... Endpunkte und demonstriert Ebenbürtigkeit bei der Gesamtreinigung des ... guter , Reinigung des ... (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ) , ... der MORA-Studie der Phase III für NER1006 (1 ...
(Date:5/24/2016)... Celsion Corporation (NASDAQ: CLSN ... an update on its ongoing OVATION study, a ... the Company,s DNA-based immunotherapy, with the standard of ... advanced ovarian cancer who will undergo neoadjuvant chemotherapy ... IL-12 DNA plasmid vector formulated as a nanoparticle ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... 27, 2016 , ... More than a third of American adults are considered ... surgery has received increased attention in recent years, as an article published ... weight loss, most people are familiar with the basic requirements of maintaining a healthy ...
(Date:5/27/2016)... ... ... With over 60 percent of acute stroke survivors being left unable to ... in the rehabilitation process has steadily increased. Ekso Bionics had been working to help ... stroke. , Ekso Bionics has now received clearance from the U.S. Food and Drug ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed ... by inspiring human interest stories, courtesy of leaders in the nursing and health ... the industry, from leading advocates and associations—namely Jones & Bartlett Learning. , Jones ...
(Date:5/26/2016)... ... ... There are many ways to cook a hot dog, but new research commissioned ... dogs straight off the grill. Of the 90 percent of Americans who say they ... hot dog, far outpacing other cooking methods such as steaming (12 percent), microwaving (9 ...
(Date:5/26/2016)... , ... May 26, 2016 , ... Connor Sports, ... basketball as a partner for the Tamika Catchings Legacy Tour that will ... industry leader in hardwood basketball surfaces in all forms and levels of the game, ...
Breaking Medicine News(10 mins):